Cue Biopharma Inc. (CUE)
NASDAQ: CUE
· Real-Time Price · USD
0.73
0.01 (1.07%)
At close: Sep 18, 2025, 3:59 PM
0.71
-2.75%
After-hours: Sep 18, 2025, 04:09 PM EDT
1.07% (1D)
| Bid | 0.71 |
| Market Cap | 56.11M |
| Revenue (ttm) | 8.29M |
| Net Income (ttm) | -38.9M |
| EPS (ttm) | -0.51 |
| PE Ratio (ttm) | -1.43 |
| Forward PE | -1.64 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.77 |
| Volume | 70,365 |
| Avg. Volume (20D) | 304,717 |
| Open | 0.73 |
| Previous Close | 0.72 |
| Day's Range | 0.73 - 0.77 |
| 52-Week Range | 0.45 - 1.99 |
| Beta | 1.59 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for CUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCue Biopharma Inc. is scheduled to release its earnings on
Nov 13, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-1.45%
Cue Biopharma shares are trading higher after the ...
Unlock content with
Pro Subscription
2 months ago
+8.67%
Cue Biopharma shares are trading higher after the company announced it received FDA pre-IND feedback for CUE-401 autoimmune therapy.
